While at a Big Pharma, Simon Westbrook had an idea for a complex fusion chimera protein he believed could interrupt the neurotrophin pathway and have a profound impact on chronic pain and joint degeneration in osteoarthritis patients. He formed Levicept to develop this idea and being a true virtual company, he needed a CDMO. By his own admission, he was looking to work with the best.
After a consultant recommended working with Lonza early on, Simon bonded with Lonza’s scientists in Cambridge, UK as they worked together on coupling the extracellular domain to an IGGFC. With this being such a complex protein, flexibility was required in the process and a lot was learned along the way. The molecule demonstrated the differentiating efficacy Simon was looking for, and is now in Phase II.
Learn more about Levicept’s journey with Lonza from Founder & CEO, Simon Westbrook.